Non-Small Cell Lung Cancer Treatment Market Outlook:
Non-Small Cell Lung Cancer Treatment Market size was valued at USD 17.9 billion in 2024 and is estimated to reach USD 42.9 billion by the end of 2037, exhibiting a CAGR of 9.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-small cell lung cancer treatment is estimated at USD 18.9 billion.
According to the report published by the American Cancer Society (ACS), more than 234,500 new cases of lung cancer were registered in 2037. Among the new registered cases, 80% are suffering from the non-small lung cancer risk. The aging population is at high risk of non-small lung cancer due to the practice of smoking and exposure to pollution. According to the report published by the World Health Organization, more than 2 million cases of lung cancer are registered in the global platform, which raises the demand for non-small cell lung cancer treatment.
The supply chain management comprises complex logistics and sourcing of API to manufacture the drugs for non-small cell lung cancer treatment. Asia is the leading producer of API that are required for oncology drugs. On the contrary, linear accelerators used within radiation therapy are mainly manufactured in the U.S., Germany, and Japan. As per the analysis of the U.S. Bureau of Labor Statistics, 4.6% growth is observed in the producer price index for biologics production R&D and a 6.2% rise in the consumer price index for cancer care. The cost of the product increased due to a higher rate of R&D and biological manufacturing, which directly raised the cost of treatment.
Non-Small Cell Lung Cancer Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Higher patient pool: Unhealthy lifestyle and growing pollutants in the environment are adversely impacting the lung condition of the population, leading to an increased number of cases of non-small cell lung cancer. Global data analysis shows that more than 80% of the global lung cancer cases are from Europe and Germany, with a gradual rise in diagnosis. Advancement within the healthcare quality accelerates the patient pool for speedy recovery from health risks. As per the study of the Agency for Healthcare Research and Quality, early diagnosis and intervention lead to recovery through therapeutic intervention. This ensured raised awareness within the non-small cell lung cancer treatment market and achieved a growth in early diagnosis and elevated market demand for non-small cell lung cancer treatment.
- Innovation and clinical trials: Constant research and development directed the market toward innovation that ensured better patient outcomes. It is anticipated that innovations such as targeted therapy and advancements in immune oncology will lead to market expansion. Companies, includingAstraZeneca, achieved clearance for Osimertinib that ensures first-in-class treatment for patients dealing with non-small cell lung cancer. The Food and Drug Administration (FDA) approval provided adequate guidance and legal alignment for the checkpoint factor of inhibitor and targeted therapies. This helped to bring better efficiency within the treatment landscape and ensure better patient outcomes. For instance, clinical trials are performed at a higher rate in Asia Pacific and North America for biomarker-based therapy to accelerate the non-small cell lung cancer treatment market performance.
Manufacturing Strategies to Ensure Non-Small Cell Lung Cancer Treatment Expansion
Three core strategies are addressed that strengthen the market performance, like immunotherapy dominance, market expansion, and biomarker-driven target therapies. Companies such as Roche and Merck achieved 25% of the non-small cell lung cancer treatment market share with the help of the introduction of PD-1/PD-L1 inhibitors. On the contrary, AstraZeneca focused on EGFR inhibitors to achieve a market share of more than 65% as per the reporting of the National Health Institution in 2024. Demand-based pricing strategy is one of the most efficient factors that led BeiGene to achieve a sales surge of more than 140% in the market of China.
Revenue Growth Opportunities (2023-2044)
|
Company |
Strategy Implemented |
Projected Revenue Impact (USD) |
Implementation Year |
|---|---|---|---|
|
Merck |
Introduction of Keytruda label expansions |
+2 billion |
2023 |
|
Roche |
Application of Tecentriq combo therapies |
+1.9 billion |
2023 |
|
AstraZeneca |
Aligning with the Tagrisso adjuvant approval |
+1.6 billion |
2022 |
|
BeiGene |
Investment in the Chinese market penetration |
+925 million |
2021 |
Key Market Dynamics for Historical Patient Growth
Significant growth is experienced in the non-small cell lung cancer treatment market from 2010 to 2020. Aging demographics, prevalence of smoking, and advanced diagnostic technology are the three leading aspects that have elevated the historical growth of patients. Raised awareness and better diagnostics infrastructure elevated the registered cases of non-small cell lung cancer in the U.S., Germany, and Japan. Emerging economies acted as a catalyst for the markets of India and China to gain a higher number of patients due to rapid urbanization, lifestyle changes, and many other factors. Innovative treatment and higher rate of investment demand elevated gradually with the rise in the number of patients worldwide, which resulted in revolutionizing the non-small cell lung cancer treatment market towards growth.
NSCLC Patient Growth (2010–2020) by Country
|
Country |
201o Procedures (millions) |
2020 Procedures (millions) |
CAGR (%) |
|
U.S. |
185 |
220 |
16.9% |
|
Germany |
49 |
55 |
15.8% |
|
France |
42 |
49 |
17.7% |
|
Spain |
31 |
37 |
20.2% |
|
Australia |
13 |
16 |
25.3% |
|
Japan |
62 |
71 |
16.9% |
|
India |
51 |
83 |
60.5% |
|
China |
105 |
162 |
60.3% |
Challenges
- Government control on the price cap and reimbursement issues: Maintaining a balance with the cost of production and the revenue accumulation for the business often faces barriers due to the government control on the price caps. As per the regulation introduced by the EU’s Health Technology Assessment, a reduction on the immunotherapy process of up to 22% is conducted in Germany to ensure reimbursement. Collaborating with the national health agencies led the companies to bear high losses due to the price control. According to the data published by the World Health Organization, budget constraints lead the low-income countries to exclude the expenses of the non-small cell lung cancer treatment from national formularies. The high cost of the treatment created a high disparity in accessibility for patients due to limited reimbursement policies in the global platform.
Non-Small Cell Lung Cancer Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.8% |
|
Base Year Market Size (2024) |
USD 17.9 billion |
|
Forecast Year Market Size (2037) |
USD 42.9 billion |
|
Regional Scope |
|
Non-Small Cell Lung Cancer Treatment Market Segmentation:
Distribution Channel Segment Analysis
Based on distribution channel, the hospital pharmacies are anticipated to grow by 56% in 2037. As per the study of the Centers for Disease Control and Prevention, more than 75% of the immunotherapy is infused under the hospital infrastructure setup. This increases the demand for hospital pharmacies as a distribution channel in the non-small cell lung cancer treatment market. According to the assessment of the FDA, 90% of the hospitals are equipped with PD-1 inhibitor cold storage that ensures conducting the therapy at a wide level. Apart from that, fast claim for reimbursement is initiated under hospital pharmacies that create a way for higher accessibility for the patients.
Treatment Type Segment Analysis
Based on treatment type, the immunotherapy segment possesses high performance ability in the non-small cell lung cancer treatment market with a 42.5% share. Approval conducted by the Food and Drug Administration for the combo therapy ensures better patient outcomes. The combo therapy includes the assimilation of pembrolizumab and chemotherapy, which enriched the functioning of immunotherapy in the concerned market. The report published by the National Institute of Health addressed that more than 15% increase in the five-year survival rate of the patient through the implementation of immunotherapy in comparison to chemotherapy alone. Expansion of Medicare coverage for immunotherapy is expanded according to the reporting of the Centers for Medicare & Medicaid Services, which raised accessibility of the market.
Our in-depth analysis of the non-small cell lung cancer treatment market includes the following segments:
|
Segment |
Subsegment |
|
Therapy Type |
|
|
Distribution Channel |
|
|
Therapy Line |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Non-Small Cell Lung Cancer Treatment Market- Regional Analysis
North America Market Insights
North America is poised to accumulate the largest market share of 48.5% by 2037 within the global market of non-small cell lung cancer treatment market. Availability of better research and development environment has flourished in the North American market to achieve dominance in the concerned market. Leading innovative biopharma companies have their headquarters in the North America region. The availability of high-quality clinical trials led to more than 45% of the global oncology trials being conducted in North America. Expanded rate of reimbursement leveraged the non-small cell lung cancer treatment market accessibility and raised demand for non-small cell lung cancer treatment. According to the report published by the Centers for Disease Control and Prevention, lung cancer is the second most common health risk factor that results in higher levels of patient growth and dominant performance of the concerned market.
In the U.S. market, the adoption of immunotherapy accelerated the growth of the non-small cell lung cancer treatment market. According to the report published by the National Institute of Health, more than 50% of the treatment revenue is generated from immunotherapy in 2023. Medicare spending is expected to increase by up to 16% in 2024, which is approximately USD 790 million. This ensured higher Medicare coverage for the pembrolizumab and nivolumab. Federal investment is also elevated to approximately USD 4.5 billion, which is almost 9,2% of the oncology budget. The practice of early screening has increased in the U.S., that reduced the later-stage diagnosis at a rate of 10%.
Asia Pacific Market Insights
The Asia Pacific market is expected to accelerate with a market share of 18.5% by 2037. The growing rate of incidence of lung cancer and better diagnostic infrastructure are the driving factors to make the region an emerging region within the global market of non-small cell lung cancer treatment. According to the report of the World Health Organization, demographic shift in Asia Pacific is one of the primary factors contributing to the growth of lung cancer. Adoption of targeted therapies and immunotherapy gained a higher rate among the patients in the Asia Pacific. Clinical trial regulations are developed and made low-cost cost which has turned the region to be the hub of global clinical trials. Government spending through varied schemes like the Ayushman Bharat Program in India and many more ensured a better reimbursement rate to reduce inequality in accessibility within the concerned market.
The non-small cell lung cancer treatment market in China holds the dominant regional market share. According to the assessment of the National Medical Products Administration, more than 1.4 million patients diagnosed with lung cancer in 2023. China possesses more than 35% of the lung cancer cases within the global market. High patient pool ability led China to dominate the regional market. Government spending is elevated to 14.5%, which amounts to approximately more than 4 billion in 2024. This helped the healthcare system to cover more than 65% cost of immunotherapy. Innovation in the non-small cell lung cancer treatment therapy is supported through the National Reimbursement Drug List.
Key Non-Small Cell Lung Cancer Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
A highly consolidated market is experienced in the non-small cell lung cancer treatment market. More than 50% of the non-small cell lung cancer treatment market share is accumulated by top players like Roche, Merck, and so on. The key strategies that are implemented to derive a competitive edge include immunotherapy dominance, targeted therapy expansion, biosimilar competition, and expansion in the Asia Pacific market. Companies such as Merck launched Keytruda and BMS’s Opdivo led to a significant increase in their sale and directed revenue accumulation of more than USD 20 million in 2023. AstraZeneca focused on targeted therapy expansion through launching Tagrisso and Alunbrig, which delivered a competitive edge to the business. Business firms, includingDr. Reddy’s, Biocon relied on cost-controlled production and delivered an affordable range of products to the market.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Market Share (2024) |
Industry Focus |
|
Roche |
Switzerland |
12.8% |
Immunotherapy (Tecentriq) & targeted therapies (Alecensa) |
|
Merck & Co. |
U.S. |
12.1% |
Keytruda (pembrolizumab) dominates the PD-1 inhibitor market |
|
Bristol-Myers Squibb |
U.S. |
10.5% |
Opdivo (nivolumab) and combo therapies for advanced NSCLC |
|
AstraZeneca |
UK |
9.9% |
Tagrisso (osimertinib) for EGFR-mutated NSCLC |
|
Pfizer |
U.S. |
7.8% |
Xalkori (crizotinib) & Lorbrena (ALK inhibitors) |
|
Novartis AG |
Switzerland |
xx% |
Targeted therapies (Zykadia) and CAR-T cell research |
|
Takeda |
Japan |
xx% |
Alunbrig (brigatinib) for ALK+ NSCLC |
|
Eli Lilly |
U.S. |
xx% |
Retevmo (selpercatinib) for RET-fusion NSCLC |
|
Daiichi Sankyo |
Japan |
xx% |
Enhertu (trastuzumab deruxtecan) for HER2-mutated NSCLC |
|
Amgen |
U.S. |
xx% |
Lumakras (sotorasib) for KRAS G12C mutations |
|
BeiGene |
China |
xx% |
Tislelizumab (PD-1 inhibitor) approved in China and/EU |
|
Sanofi |
France |
xx% |
Libtayo (cemiplimab) for PD-L1 high NSCLC |
|
Regeneron |
U.S. |
xx% |
Libtayo (collaboration with Sanofi) |
|
Celltrion |
South Korea |
xx% |
Biosimilars (Truxima) and immune checkpoint inhibitors in development |
|
Eisai Co., Ltd. |
Japan |
xx% |
Biosimilars (rituximab) and generic oncology drugs |
|
Dr. Reddy’s |
India |
xx% |
Biosimilars (pegfilgrastim) and targeted therapies |
|
Biocon |
Inda |
xx% |
Domestic PD-1 inhibitors and chemotherapy agents |
|
CSPC Pharma |
China |
xx% |
Domestic PD-1 inhibitors and chemotherapy agents |
|
Pharmaniaga |
Malayasia |
xx% |
Local distribution and generic oncology drugs |
|
CSL |
Australia |
xx% |
Emerging immuno-oncology pipeline |
Below are the areas covered for each company in the wood flooring market:
Recent Developments
- In September 2024, Roche launched Tecentriq Hybreza, which is considered to be the first subcutaneous anti-PD-L1 therapy. This resulted in a reduction of administration timing maximum of 9 minutes, resulting in better clinical efficiency.
- In December 2024, Xcovery Holdings introduced Ensartinib, which demonstrated the median progression-free scopes of survival of 25.9 months. It enables to offering higher level of first-line treatment opportunity to the patients.
Author Credits: Radhika Pawar
- Report ID: 3024
- Published Date: Jun 19, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Non-Small Cell Lung Cancer Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
